Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section
NCT ID: NCT02044549
Last Updated: 2021-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
300 participants
INTERVENTIONAL
2014-06-30
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bimanual Uterine Compression to Reduce Blood Loss and Prevent Postpartum Haemorrhage After Vaginal Delivery
NCT02136719
The Cervix as a Natural Tamponade in Postpartum Hemorrhage Caused by Placenta Previa and Placenta Previa Accreta
NCT02590484
Uterine Cavity and Blood Flow After Conservative Management of Placenta Previa/Accreta
NCT02878187
Conservative Surgery for Abnormally Invasive Placenta: A New Technique
NCT04193618
Fertility Post Placenta Accrete
NCT02821702
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Prevention of postpartum haemorrhage (PPH) after cesarean section (CS) had been evaluated by measurement of drop of Hemoglobin and hematocrit, incidence of PPH and number of subjects needed additional oxytocic
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
carbetocin
single 100 μg IV dose of carbetocin (150 women) after fetal extraction and before placental removal.
carbetocin
Oxycontin analogue
Syntometrine
Intravenous combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal.
Syntometrine
Uterotonins
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
carbetocin
Oxycontin analogue
Syntometrine
Uterotonins
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Noncomplicated pregnancy.
Exclusion Criteria
* Patients with coagulopathy
* preeclamptic women
* known sensitivity to oxytocin or methergine were excluded
18 Years
39 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed M Maged, MD
Assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed Maged, MD
Role: PRINCIPAL_INVESTIGATOR
Ass prof kasr aini medical school
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ahmed Maged
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Carbitocin
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.